These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 17255295)

  • 1. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Pantuck AJ; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Margulis V; Matin SF; Wood CG
    Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debulking nephrectomy in metastatic renal cancer.
    Flanigan RC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
    Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presurgical therapy in metastatic renal cell carcinoma.
    Jonasch E
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
    Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
    Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
    Bex A; Powles T
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cytoreductive nephrectomy in renal cell carcinoma.
    Chiong E; Wood CG; Margulis V
    Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.
    Levy DA; Swanson DA; Slaton JW; Ellerhorst J; Dinney CP
    J Urol; 1998 Apr; 159(4):1168-73. PubMed ID: 9507824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The once and future role of cytoreductive nephrectomy.
    Neill MG; Jewett MA
    Urol Oncol; 2008; 26(4):346-52. PubMed ID: 18367110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression.
    Flanigan RC
    Urol Clin North Am; 1987 Nov; 14(4):757-62. PubMed ID: 3314066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.